• Vera Therapeutics stock is building positive momentum. Why is VERA stock advancing?
Vera Therapeutics Awaits Key FDA Decision
Over the past month, the stock has gained around 30%.
With the action date on July 7, the company seeks accelerated approval of atacicept in patients with IgA Nephropathy (IgAN), an autoimmune kidney disease that occurs when immunoglobulin A (IgA) antibodies build up in the kidneys.
The buildup causes inflammation that damages the glomeruli (tiny filters in the kidneys), making it harder to filter waste from the blood.
